Try a new search

Format these results:

Searched for:

in-biosketch:yes

person:babbj01

Total Results:

549


Biological markers of risk in nipple aspirate fluid are associated with residual cancer and tumour size

Sauter ER; Ehya H; Babb J; Diamandis E; Daly M; Klein-Szanto A; Sigurdson E; Hoffman J; Malick J; Engstrom PF
We previously demonstrated that nipple aspirate fluid (NAF) can be obtained from virtually all non-Asian women between the ages of 30 and 72. The focus of this report is to (1) determine the association of candidate markers of breast cancer risk in NAF obtained from fresh mastectomy specimens with residual breast carcinoma, and (2) evaluate the association of the markers with breast tumour progression. Nipple aspiration was performed on 97 specimens. Cytology, DNA index (including % hypertetraploid cells), cell cycle parameters (S phase fraction, % cells in G2/M), prostate-specific antigen (PSA), epidermal growth factor (EGF), testosterone, carcinoembryonic antigen (CEA) and prostaglandin D synthase (PGDS) were evaluated in NAF for their association with (1) residual ductal carcinoma in situ (DCIS) or invasive cancer, and (2) pathologic tumour size. NAF was obtained from 99% (96/97) of specimens. Atypical and malignant NAF cytology were significantly associated with residual DCIS or invasive cancer (P = 0.001) and with larger tumours (P = 0.004). One hundred per cent and 88% of subjects with malignant and atypical NAF cytology, respectively, had residual carcinoma. The percentage of cells in G2/M and DNA index were associated both with risk of residual carcinoma (P = 0.01 for each) and larger tumour size (DNA index, P = 0.03; G2/M, P = 0.05), although neither biomarker improved the ability of NAF cytology, to predict residual breast cancer. Higher DNA index was associated with atypical cytology (P = 0.0001). In summary, atypical and malignant NAF cytology are associated with larger tumour size, and are highly predictive of residual carcinoma after needle or excisional biopsy of the breast
PMCID:2374332
PMID: 10584885
ISSN: 0007-0920
CID: 43780

Non T1 or T2-weighted whole brain N-acetylaspartate quantitation using proton magnetic resonance spectroscopy [Meeting Abstract]

Gonen, O; Viswanathan, KA; Babb, JS; Udupa, JK; Grossman, RI
ISI:000083347301272
ISSN: 0033-8419
CID: 105115

Importance of timing and length of administration of angiogenesis inhibitor TNP-470 in the treatment of K12/TRb colorectal hepatic metastases in BD-IX rats

Watson, J C; Sutanto-Ward, E; Osaku, M; Weinstein, J K; Babb, J S; Sigurdson, E R
BACKGROUND: The timing and length of administration of angiogenesis inhibitor TNP-470 was altered to evaluate the effect on disease progression in a rat model of colorectal hepatic metastases. METHODS: Pair-fed BD-IX rats, injected intrasplenically with rat colon adenocarcinoma K12/TRb cells at day 0, were randomized to receive subcutaneous injections of either placebo or 15 mg/kg TNP-470 on alternate days: for 2 weeks beginning 24 hours after tumor inoculation ('Early'), for 4 weeks beginning 24 hours after tumor inoculation ('Prolonged'), or for 2 weeks beginning at day 15 after macroscopic tumor nodules were confirmed ('Delayed'). Response to treatment was evaluated by counting tumor nodules on the surface of the liver at laparotomy on day 14 and 28 after tumor inoculation. The animals were followed for survival and cause of death. RESULTS: Maximal suppression of hepatic metastases at day 28 required 4-week rather than 2-week TNP-470 administration. Prolonged TNP-470 administration resulted in significantly fewer hepatic metastases at day 28 compared to control (P < .05). Early and prolonged TNP-470 improved survival (Wilcoxon test, P < .05) compared with delayed TNP-470 and placebo. Delayed TNP-470 administration did not increase survival or significantly diminish the number of metastases at day 28 compared with placebo. CONCLUSIONS: These data suggest that prolonged adjuvant antiangiogenic therapy may suppress colorectal hepatic micrometastases
PMID: 10455906
ISSN: 0039-6060
CID: 111574

Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinoma

Cheng, J D; Werness, B A; Babb, J S; Meropol, N J
The cyclin-dependent kinase inhibitors (CDIs) p27kip1 and p21waf1/cip1 are key cell cycle-negative regulatory enzymes. The objective of this study was to correlate expression of p27kip1 and p21waf1/cip1 with survival, chemotherapy responsiveness, and expression of the proliferation marker Ki-67 in patients with advanced colorectal cancer. Immunohistochemistry was performed with antibodies to p27kip1, p21waf1/cip1, and Ki-67 on samples from 66 patients with metastatic colorectal carcinoma. Interpretation was performed by visual inspection and automated image analysis. Patients who obtained a response to chemotherapy had greater p21waf1/cip1 tumor staining with a mean of 10.0 positive cells/high-powered field, compared with 4.5 positive cells/high-powered field for nonresponders (P = 0.03). A positive Spearman correlation was seen between Ki-67 and p27kip1 (r = 0.48; P = 0.0001), as well as between Ki-67 and p21waf1/cip1 (r = 0.48; P = 0.0001). A trend toward shorter survival was seen in patients with positive specimens (median survival of 10 months for patients with both p27kip1- and p21waf1/cip1-positive specimens, compared with 22 months for patients with neither p27kip1- nor p21waf1/cip1-positive specimens). In contrast to that previously reported in normal colonic mucosa or early-stage colorectal cancer, we observed positive correlations of Ki-67 with both p27kip1 and p21waf1/cip1, a trend toward greater CDI staining indicating worse prognosis, and greater p21waf1/cip1 staining in tumors that were chemosensitive. These findings suggest that in the metastatic setting, CDIs may show altered function, compared with their role in the normal cell cycle
PMID: 10353738
ISSN: 1078-0432
CID: 111575

Total brain N-acetylaspartate concentration in normal, age-grouped females: quantitation with non-echo proton NMR spectroscopy

Gonen O; Viswanathan AK; Catalaa I; Babb J; Udupa J; Grossman RI
The intra-individual and inter-individual variations of the global N-acetylaspartate (NAA) concentration were measured in a cohort of five 42+/-5 year-old normal females. The total NAA signal from the whole head was obtained with non-localized non-echo proton spectroscopy (1H-MRS) and converted into absolute mole amounts using phantom replacement. Since NAA is assumed to be present only in neurons, its concentration was obtained by dividing these mole amounts with the brains' volume, calculated from high resolution MRI. The key feature of the procedure is its near-complete suppression of the intense subcutaneous and bone marrow lipids' signals, whose chemical shifts neighbor and underlay the NAA. This was achieved by exploiting the lipids' much shorter T1s, compared to that of NAA, for destructive interference of their signals in co-addition following alternating, nonselective 180 degrees inversions. The average global, inter-individual NAA concentration in that group was found to be 10.63 mM with a 95% confidence interval of 10.43-10.82 mM
PMID: 9797150
ISSN: 0740-3194
CID: 27742

Prostate-specific antigen production in the female breast: association with progesterone

Sauter ER; Babb J; Daly M; Engstrom PF; Ehya H; Malick J; Diamandis E
Prostate-specific antigen (PSA) is produced by the female breast. Prior in vitro evidence suggests that PSA expression in breast epithelial cells is regulated by androgens and progestins but not estrogens. The purpose of this study was to determine whether (a) PSA expression in breast nipple aspirate fluid (NAF) and in serum is influenced by progesterone (PG); (b) the ability to obtain NAF decreases with repeated breast aspirations; and (c) PSA in NAF correlates with abnormal NAF cytology. Eight pre- and three postmenopausal women with no breast cancer risk factors were enrolled in a pilot study and had NAF and serum collected every 3-4 days for a month to evaluate the influence of serum PG, luteinizing hormone, estradiol, and follicle-stimulating hormone on PSA in serum and in NAF. NAF was obtained in 99% (112 of 113) of aspiration visits. Median, mean, and peak NAF but not serum PSA levels were higher in pre- than in postmenopausal subjects. NAF PSA levels were associated with the rise or peak in serum PG in seven of eight premenopausal women (seven of seven with a PG surge) and in zero of three postmenopausal women. Considering all 11 women, there was an association between NAF PSA and PG (P = 0.005) but not luteinizing hormone, estradiol, or follicle-stimulating hormone. NAF volume did not significantly change over time. Atypical hyperplasia (9%) and hyperplasia without atypia (36%) were identified in the NAF of a subset of the subjects. Median, mean, and peak levels of NAF PSA (P = 0.05, 0.05, and 0.10, respectively) were higher in subjects with normal versus hyperplastic cytology. PSA production in the breast increases in association with PG. With aspiration every 3-4 days, NAF volume does not significantly decrease over time. NAF cytology and PSA levels in NAF may help identify women at increased breast cancer risk. Changes in biomarkers of breast cancer risk in NAF (including PSA and cytology) may predate mammographic abnormalities. NAF may, therefore, be useful as a breast cancer screening tool for young women who are not recommended to undergo mammography and as an adjunct to screen women who have mammograms performed
PMID: 9568787
ISSN: 1055-9965
CID: 43781

The effect of digoxin on mortality and morbidity in patients with heart failure

Perry, G; Brown, E; Thornton, R; Shiva, T; Hubbard, J; Reddy, KR; Doherty, JE; Cardello, FP; Fast, A; Radford, MJ; Folger, JS; Bhaskar, G; Zoble, RG; Sridharan, V; Sridharan, MR; Loungani, RR; Gheorghiade, M; Hsieh, A; Tommaso, C; Mansuri, M; Guess, MA; Akhtar, S; Wagner, S; Hagan, K; McIntyre, KM; Ruble, P; Moten, M; Riley, A; Pierpont, G; Anand, I; Patel, G; Puram, BS; Eladasari, BR; Karnegis, J; Gillie, E; Crawford, MH; Graettinger, WF; Shah, A; Sacco, J; Chaudhry, MA; Dolen, D; ElSherif, N; BekheitSaad, S; Campos, EE; Greene, JG; Khanijo, V; Kumar, U; Mallis, GI; Mookherjee, S; DibnerDunlap, M; Gupta, SC; Danisa, K; Thadani, U; Tan, A; Rajachar, M; Amidi, M; OReilly, MV; Hassapoyannes, CA; Davies, ML; Kumar, VA; Okerson, D; Ramanathan, KB; Putatunda, B; Gollapudi, A; Montero, A; Mohanty, PK; Lui, C; Thagirisa, S; Lee, RW; Glatter, TR; Bodine, K; Roberts, D; Bertoglio, M; Dennish, GW; Sarma, RJ; Gregoratos, G; Rausch, DC; Pitt, WA; Kennelly, BM; Fahrenholtz, D; Gordon, R; Horwitz, L; Rothbart, R; Nutting, P; Lutz, L; Copen, DL; Rashkow, A; Babb, J; VanVoorhees, L; Silverman, A; Stillabower, ME; Miller, AB; NguyenPho, HT; Safford, RE; Fishman, S; Neiman, JC; Stein, M; Dominguez, JC; Abernathy, GT; Nair, PH; Goodman, LS; Cook, TH; Wickemeyer, WJ; Berkson, DM; Mathew, J; Richman, HG; Lubell, DL; Lang, R; Zajac, EJ; Rosenstein, R; Silver, MA; Shanes, JG; Kelly, KJ; Pequignot, MH; Campbell, R; Kirlin, PC; Ziperman, DB; Denny, DM; Gamble, L; Weiss, M; Kaimal, PK; Dhurandhar, RW; Ventura, H; Godley, ML; Pu, C; Schick, EC; Barbour, DJ; Salmon, D; Goldstein, M; Effron, MB; Fleg, JL; Baughman, KL; Weiss, R; Ericson, K; Sturrock, WA; Heinsimer, J; Timmis, GC; Smith, S; Shrestha, DD; Duvernoy, WFC; Hickner, J; Lewis, BK; OBrien, TK; Yarows, SA; Willens, HJ; Mast, DJ; Johnson, TH; Rodeheffer, RJ; Siefert, M; Swenson, L; Denes, P; Gudapati, R; Charles, FR; Rich, MW; Beckham, V; Hamilton, WP; Abele, PB; Harper, DM; OKelly, RL; Forker, AD; Kahl, FR; Garrou, BW; Klang, TE; Popio, K; Mohiuddin, S; Pollak, EM; Chiaramida, A; Gregory, JJ; Papa, LA; Abrams, J; Ung, S; Jutila, CK; Croke, RP; Chiaramida, S; Lucariello, R; Rim, DA; Goldberger, MH; Kohn, RM; Graham, S; Philbin, EF; Sheesley, K; Nafziger, A; Macina, G; Hsueh, JT; Zoneraich, S; Binder, A; Weinstein, C; Morrison, J; Cameron, A; Vanderbush, E; Brown, J; Pande, PN; Lader, E; Kay, R; Bloomfield, D; Costantino, T; Heiselman, DE; Radwany, S; Smith, MR; Hobbs, RE; Fraker, TD; Frerking, TR; DeLeon, AC; Christie, LG; Toren, M; Grover, J; McBarron, FD; Harris, DE; McLean, RW; Morris, L; Zatuchni, J; Boehmer, JP; Clemson, BS; Lipshutz, H; Small, RS; Ufret, R; LugoRodriquez, JE; Khan, AH; Yousefian, M; Friesinger, GC; Ely, D; Farmer, JA; Young, JB; Payne, RM; Fowles, RE; Lee, AB; Shalev, Y; AlBitar, I; Schroeder, GS; Radant, L; Hankey, TL; Rezkalla, S; Groden, DL; Teo, KK; Humen, DP; Wong, D; Greenwood, PV; Talibi, T; Hui, W; Klinke, WP; Senaratne, MPJ; Goeres, M; Hughes, DF; Sayeed, MAR; Roth, DL; Belenkie, I; Manyari, DE; Borgersen, K; Read, L; Kinloch, D; Reid, R; Barber, NC; Horner, BA; Kenefick, G; Kuritzky, RA; Imrie, JR; Wagner, KR; Rabkin, SW; Mizgala, HF; Tarry, L; Dodek, A; Kornder, JM; Ashton, T; Barr, D; Dufton, J; Sweeny, R; Morris, A; Bessoudo, R; Marr, D; Milton, JR; Thompson, B; Robinson, V; Sussex, BA; Tobin, M; McMahon, DP; Folkins, D; Crowell, R; Lalonde, LD; Koilpillai, C; Hatheway, RJ; OReilly, MG; Machel, T; Hack, I; Stewart, JW; Tanser, PH; Sullivan, B; Hagar, S; Quinn, B; Davies, RA; Baird, MG; Williams, WL; LeMay, M; Higginson, L; Turek, M; Sochowski, RA; Weeks, A; Jacobs, MH; Baigrie, R; DeVilla, MA; Vertes, G; Bozek, B; Goode, JE; Ricci, AJ; Swan, J; Fell, DA; LevinoffRoth, SN; Arnold, JMO; Patrick, L; Southern, RF; Rinne, C; Brisbin, D; DeYoung, JP; Baitz, T; Vizel, S; Minkowitz, J; Letarte, P; Chan, YK; Kwok, KK; Nawaz, S; Ganjavi, F; Yao, L; Misterski, J; Raco, DL; Hess, AR; Kuruvilla, G; Silverberg, L; Borts, D; Fulop, JC; Weingert, ME; Carter, RP; Sahay, BM; Hickey, JE; Lalonde, G; Gosselin, G; Bourassa, MG; Goulet, C; Joyal, M; Methe, M; Honos, G; Fitchett, D; Serpa, A; Sestier, F; Roberge, G; Latour, Y; Rondeau, C; Gossard, D; Lenis, JHF; Brossoit, R; Simard, L; Delage, F; Auger, P; Saulnier, D; Talbot, P; Beaudoin, J; Campeau, J; Pruneau, G; Tamilia, M; Boutros, G; Comeau, B; Starra, R; StHilaire, R; Veilleux, J; Mercier, M; Poulin, JF; Maclellan, K; Lepage, S; Rouleau, JL; Bruinsma, N; Levesque, C; DeLarochelliere, R; LeBlanc, M; Kouz, S; Kiwan, GS; Laforest, M; Brooks, J; Bouchard, G; Gervais, PB; Brophy, J; Gagnon, J; Habib, N; Basu, AK; Lutterodt, AT; Khouri, M; Gorlin, R; Egan, D; Garg, R; Yusuf, S; Montague, T; Smith, TW; Cohn, JN; Dagenais, GR; Davies, R; Johnstone, DE; Fye, C; Sather, MR; Deykin, D; Francis, G; Collins, JF; Williford, WO; Singh, BN
Background The role of cardiac glycosides in treating patients with chronic heart failure and normal sinus rhythm remains controversial. We studied the effect of digoxin on mortality and hospitalization in a randomized, double-blind clinical trial. Methods In the main trial, patients with left ventricular ejection fractions of 0.45 or less were randomly assigned to digoxin (3397 patients) or placebo (3403 patients) in addition to diuretics and angiotensin-converting-enzyme inhibitors (median dose of digoxin, 0.25 mg per day; average follow-up, 37 months). In an ancillary trial of patients with ejection fractions greater than 0.45, 492 patients were randomly assigned to digoxin and 496 to placebo. Results In the main trial, mortality was unaffected. There were 1181 deaths (34.8 percent) with digoxin and 1194 deaths (35.1 percent) with placebo (risk ratio when digoxin was compared with placebo, 0.99; 95 percent confidence interval, 0.91 to 1.07; P = 0.80). In the digoxin group, there was a trend toward a decrease in the risk of death attributed to worsening heart failure (risk ratio, 0.88; 95 percent confidence interval, 0.77 to 1.01; P = 0.06). There were 6 percent fewer hospitalizations overall in that group than in the placebo group, and fewer patients were hospitalized for worsening heart failure (26.8 percent vs. 34.7 percent; risk ratio, 0.72; 95 percent confidence interval, 0.66 to 0.79; P < 0.001). In the ancillary trial, the findings regarding the primary combined outcome of death or hospitalization due to worsening heart failure were consistent with the results of the main trial. Conclusions Digoxin did not reduce overall mortality, but it reduced the rate of hospitalization both overall and for worsening heart failure. These findings define more precisely the role of digoxin in the management of chronic heart failure. (C) 1997, Massachusetts Medical Society. $$:
ISI:A1997WJ24000001
ISSN: 0028-4793
CID: 108143

Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: A large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure

Abernathy, GT; Abrams, J; Akhtar, S; Albitar, I; Amidi, M; Anand, IS; Arnold, JMO; Ashton, T; Aubrey, B; Auger, P; Babb, J; Baigrie, R; Baird, MG; Baitz, T; Barber, NC; Barbour, DJ; Barr, DM; Basu, AK; Baughman, KL; Beckham, V; BekheitSaad, S; Berkson, DM; Bertoglio, M; Bessoudo, R; Beaudoin, J; Bhaskar, G; Binder, A; Bloomfield, D; Bodine, K; Boehmer, JP; Borgersen, K; Borts, D; Bouchard, G; Bourassa, MG; Boutros, G; Bozek, B; Brisbin, D; Brophy, J; Brossoit, R; Brown, E; Brown, J; Bruinsma, N; Burton, G; Cameron, A; Campbell, R; Campeau, J; Campos, EE; Cardello, FP; Carter, RP; Chan, YK; Charles, FR; Chaudhry, MA; Chiaramida, A; Chiaramida, S; Chohan, A; Christie, LG; Clemson, BS; Collin, R; Cook, TH; Copen, DL; Cossett, J; Costantino, T; Crawford, MH; Croke, RP; Crowell, R; DAmours, G; Dagenais, GR; Danisa, K; Davidson, S; Davies, ML; Davies, R; Davies, RA; DeLarochelliere, R; DeLeon, AC; Delage, F; Denes, P; Dennish, GW; Denny, DM; DeVilla, MA; DeYoung, JP; Dhurandhar, RW; DibnerDunlap, M; Dodek, A; Doherty, JE; Dominguez, J; Dubbin, J; Dufton, J; Effron, MB; ElSherif, N; Eladasari, B; Fly, D; Ericson, K; Fahrenholtz, D; Fast, A; Fell, DA; Fishman, S; Fitchett, D; Fleg, JL; Flint, E; Folger, JS; Folkins, D; Forker, AD; Fowles, RE; Fraker, TD; Francis, G; Frerking, TR; Friesinger, GC; Fulop, JC; Gagnon, J; Gamble, L; Ganjavi, F; Garrou, BW; Gervais, PB; Gheorghiade, M; Gilbert, L; Gillie, E; Glatter, TR; Godley, ML; Goeres, M; Goldberger, MH; Gollapudi, A; Goode, JE; Goodman, LS; Gordon, R; Gossard, D; Gosselin, G; Goulet, C; Grant, C; Graettinger, WF; Greene, JG; Greenwood, PV; Gregoratos, G; Gregory, JJ; Groden, DL; Grover, J; Gudapati, R; Guess, MA; Gupta, SC; Habib, N; Hack, I; Hamilton, WP; Hankey, TL; Hanna, M; Harper, D; Harris, DE; Hassapoyannes, CA; Hatheway, RJ; Heinsimer, J; Pequignot, MH; Heiselman, DE; Hess, AR; Hickner, J; Hickey, JE; Higgins, T; Higginson, L; Hill, L; Hobbs, RE; Honos, G; Horner, BA; Horwitz, L; Hsieh, A; Hsueh, JT; Hubbard, J; Hughes, DF; Hui, W; Imrie, JR; Jacobs, MH; Jarmukli, N; Johnson, TH; Johnstone, D; Jutila, CK; Kadri, N; Kahl, FR; Kaimal, PK; Karnegis, J; Kay, R; Kelly, KJ; Kenefick, G; Kennelly, BM; Kent, E; Khan, AH; Khanijo, V; Khouri, M; Kinloch, D; Kirlin, PC; Kiwan, GS; Kline, MD; Kohn, RM; Koilpillai, C; Kornder, JM; Kouz, S; Kumar, VA; Kumar, U; Kuntz, A; Kuritzky, RA; Kuruvilla, G; Kwok, KK; Lader, E; Laforest, M; LaForge, D; Lalonde, G; Lalonde, L; Lang, RM; Latour, Y; Lawal, O; LeBlanc, MH; Lee, AB; Lee, RW; Legault, C; Lemay, M; Lenis, JHF; Lepage, S; Letarte, P; Levesque, C; LevinoffRoth, SN; Lewis, BK; Lipshutz, H; Loungani, RR; Lowery, ML; Lubell, DL; Lucariello, R; LugoRodriguez, JE; Lui, C; Lutterodt, AT; Lutz, L; Machel, T; Macina, G; MacLellan, K; Magnan, O; Mansuri, M; Manyari, DE; Mallis, GI; Marr, D; Mast, DJ; Mathew, J; McBarron, FD; McIntyre, KM; McLean, RW; McMahon, DP; Mercier, M; Methe, M; Miller, AB; Minkowitz, J; Milton, JR; Mizgala, HF; Mohanty, PK; Mohiuddin, S; Montero, A; Mookherjee, S; Morris, A; Morris, L; Morrison, J; Moten, M; Nafziger, A; Nair, PH; Nawaz, S; Neiman, JC; Nutting, P; NguyenPho, HT; OBrien, TK; OKelly, RL; OReilly, MV; Okerson, D; Patel, G; Pande, PN; Papa, LA; Patrick, L; Payne, RM; Perry, G; Philbin, EF; Pierpont, G; Pitt, WA; Poirier, C; Pollak, EM; Popio, K; Poulin, JF; Probst, PA; Pruneau, G; Pu, C; Puram, BS; Putatunda, B; Quinn, B; Rabkin, SW; Racine, N; Raco, DL; Radant, L; Radford, MJ; Radwany, S; Rajachar, M; Ramanathan, KB; Rashkow, A; Rausch, DC; Read, L; Reddy, KR; Reid, R; Rich, MW; Ricci, AJ; Richman, HG; Riley, A; Rim, DA; Rinne, C; Roberge, G; Roberts, DK; Robinson, V; Rodeheffer, RT; Rosenstein, R; Roth, DL; Rothbart, R; Rouleau, JL; Ruble, P; Sacco, J; Safford, RE; Salmon, D; Sahay, BM; Sarma, RJ; Sayeed, MAR; Schick, EC; Schroeder, GS; Seifert, M; Senaratne, MPJ; Sestier, F; Shah, A; Shanes, JG; Sheesley, K; Silverman, A; Shiva, T; Shrestha, DD; Silver, MA; Silverberg, L; Simard, L; Singh, BN; Small, RS; Smith, MR; Smith, S; Sochowski, RA; Southern, RF; Sridharan, MR; StHilaire, R; Stein, M; Stewart, JW; Stillabower, ME; Sullivan, BHM; Sturrock, WA; Sussex, BA; Swan, J; Swenson, L; Talbot, P; Talibi, T; Tamilia, M; Tan, A; Tanser, PH; Tarry, L; Teo, KK; Thadani, U; Thagirisa, S; Thompson, B; Thornton, R; Timmis, GC; Tobin, M; Tommaso, C; Toren, M; Tsuyuki, R; Turek, M; Utley, K; Vanderbush, EJ; VanVoorhees, L; Ventura, H; Vertes, G; Vizel, S; Wagner, KR; Wagner, S; Weeks, A; Weingert, ME; Weinstein, C; Weiss, MM; Weiss, R; Wickemeyer, W; Wielgoz, A; Willens, HJ; Williams, WL; Wong, D; Yarows, SA; Yao, L; Shalev, Y; Young, JB; Yousefian, M; Zajac, EJ; Zatuchni, J; Ziperman, DB; Zoble, RG; Zoneraich, S; Gorlin, R; Sleight, P; Cohn, JN; Collins, R; Deykin, D; Hennekens, C; Kjekshus, J; Smith, TW; Tognoni, G; Collins, JF; Williford, WO; Fye, C; Sather, R; Jolly, MK; Held, CP; Verter, J; Yusuf, S; Egan, D; Garg, R; Johnstone, DE; Montague, T; Bristow, D; Engelhardt, HT; Gent, M; Hood, WB; Jones, S; Meier, P; Pitt, B; Waters, D; Arnold, JMO; Baker, A; Barnhill, S; Carew, B; Hagar, S; Liuni, C; Martin, S; Miles, R; Arthur, MM; Feldbush, MW; Highfield, DA; Hobbins, TE; Kurz, R; Leviton, SP; Libonati, JP; Moore, M; Perez, E; Mills, P; Geller, N; Hunsberger, S; Gold, J; Huang, PC; Burns, A; Caleb, H; Cline, DR; Harris, S; Hockenbrock, R; Horney, RA; Jadwin, LM; King, J; Sexton, P; Spence, ME; Chacon, F; Gagne, W; Maple, S; Martinez, G
This article provides a detailed overview of the rationale for key aspects of the protocol of the Digitalis Investigation Group (DIG) trial. It also highlights unusual aspects of the study implementation and the baseline characteristics. The DIG trial is a large, simple, international placebo-controlled trial whose primary objective is to determine the effect of digoxin on all cause mortality in patients with clinical heart failure who are in sinus rhythm and whose ejection fraction is less than or equal to 0.45. An ancillary study examines the effect in those with an ejection fraction > 0.45. Key aspects of the trial include the simplicity of the design, broad eligibility criteria, essential data collection, and inclusion of various types of centers. A total of 302 centers in the United States and Canada enrolled 7788 patients between February 1991 and September 1993. Follow-up continued until December 1995 with the results available in Spring 1996. $$:
ISI:A1996UA39800009
ISSN: 0197-2456
CID: 108145

Polarographic needle electrode measurements of oxygen in rat prostate carcinomas: accuracy and reproducibility

Yeh, K A; Biade, S; Lanciano, R M; Brown, D Q; Fenning, M C; Babb, J S; Hanks, G E; Chapman, D C
PURPOSE: The oxygenation status of tumors may be important for predicting tumor response to therapy. Previous studies with the anaplastic (R3327-AT) and well-differentiated (R3327-H) Dunning rat prostate tumors using indirect assays of tumor oxygenation indicated the relative hypoxic and radioresistant nature of the anaplastic tumor. We now report direct measurements of oxygen in these tumors made with the pO2 histograph to determine: (a) whether a significant difference in oxygenation status could be detected between them: (b) whether sequential measurements on the same tumor gave similar values; and (c) whether tumor oxygenation correlated with tumor volume. METHODS AND MATERIALS: R3327-AT and R3327-H tumors were grown in Fischer X Copenhagen rat to volumes of 1.0-7.0 cm3. Electrode measurements (100-200) were made in tumors in anesthetized animals along two parallel tracks. Repeat measurements were made at 1-5 days along different parallel tracks. Oxygen partial pressures of muscle tissue were measured and served as a normal tissue control. Statistical analyses were applied to determine whether tumor oxygen levels were different between the two tumor histologies, whether sequential measurements in the same tumor were reproducible, and whether tumor oxygenation correlated with tumor volume. RESULTS: The average median pO2 of the well-differentiated (n = 15) and the anaplastic (n = 15) tumors was 6.0 mmHg (SE +/- 1.3) and 2.2 mmHg (SE +/- 0.3), respectively. The average median pO2 of normal rat muscle (n = 15) was 23.6 mmHg (SE +/- 2.0). These values represent highly significant differences in oxygen concentration between the two tumors and rat muscle. The differences in average mean pO2 values were also highly significant. Repeat measurements in the same tumors on different days gave average median values of 4.7 and 2.2 mmHg in the R3327-H (n = 15) and R3327-AT (n = 15) tumors, respectively. For these repeat measurements, median pO2 values decreased in 15 and increased in 15 tumors, and were not significantly different from the first measurements. The average differences observed in median pO2 were 37% (SE +/- 7) and 58% (SE +/- 10) for the R3327-H and R3327-AT tumors, respectively. No significant correlation was observed between pO2 levels and the tumor volumes investigated in this study. CONCLUSIONS: The median pO2 values of the anaplastic Dunning tumors were significantly lower than those of the well-differentiated tumors (p < 0.001). Oxygen levels in both tumors were significantly lower than those measured in normal rat muscle (p < 0.00005). Repeat measurements of median pO2 in the same tumors were not significantly different for either tumor model (p > 0.5). The changes observed in pO2 distributions within individual tumors from day to day may indicate true dynamics of its oxygenation status and/or the limits of electrode measurements, by sampling along only two insertion sites. The electrode measurements of pO2 in these tumor models are reproducible and confirm previously detected oxygenation differences between the anaplastic and well-differentiated tumors
PMID: 7642408
ISSN: 0360-3016
CID: 111576